Cargando…
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607975/ https://www.ncbi.nlm.nih.gov/pubmed/31388299 http://dx.doi.org/10.2147/IJN.S217605 |
| _version_ | 1783432180804878336 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6607975 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66079752019-08-06 In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] Int J Nanomedicine Corrigendum Dove 2019-06-28 /pmc/articles/PMC6607975/ /pubmed/31388299 http://dx.doi.org/10.2147/IJN.S217605 Text en © 2019 Sreeranganathan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Corrigendum In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title_full | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title_fullStr | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title_full_unstemmed | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title_short | In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum] |
| title_sort | in vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in egfr-overexpressing gastric cancer xenografts [corrigendum] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607975/ https://www.ncbi.nlm.nih.gov/pubmed/31388299 http://dx.doi.org/10.2147/IJN.S217605 |